PROTEINA
PROTEINA announced today that it has held a kickoff meeting with Professor Janghee Woo and his research team at Emory University School of Medicine in Atlanta, to begin global clinical validation of its flagship product, PPI PathFinder BCL2 Dx.
PPI PathFinder BCL2 Dx incorporates PROTEINA’s “SPID (Single-molecule Protein Interaction Detection)” technology, enabling high-sensitivity detection of protein-protein interaction (PPI) complexes of BCL2 family proteins and more accurate prediction of any PPI inhibitors targeting the BCL2 family. In this clinical validation, PPI PathFinder BCL2 Dx will be used to predict drug responsiveness in patients with Acute Myeloid Leukemia (AML), providing clinicians with guidance for more effective prescriptions of the widespread BCL2-targeted cancer drug “Venetoclax.”
PROTEINA has previously conducted clinical validation of the same product domestically with the Hematologic Cancer Team at Seoul National University, and the findings are scheduled to be soon published in a high-profile scientific journal, Nature Biomedical Engineering, later this year.
Starting in May, PROTEINA will transport its Pi-View analysis device and related reagents to labs at Emory. Dr. Janghee Woo, a hematologist at Emory, has spearheaded a translational research laboratory focused on deciphering the molecular mechanisms underlying hematological malignancies to improve clinical outcomes. This endeavor entails the collection and examination of several hundred AML samples to investigate the molecular intricacies of the disease and pinpoint biomarkers linked to therapeutic response. PROTEINA and Dr. Woo’s research team will analyze these samples using the PPI PathFinder BCL2 Dx to validate its clinical efficacy.
Dr. Janghee Woo expressed optimism, stating, “This project will not only validate the clinical efficacy of the PPI PathFinder but also allow for collaboration across various fields through the expansion of solutions to further indications of Venetoclax.”
PROTEINA’s CEO, Tae-Young Yoon, remarked, “Having successfully completed domestic clinical validation in South Korea over the past two years, we are very excited about this large-scale clinical validation in the United States. We are committed to diligently completing the validation process as this would represent the first step towards wide use of PROTEINA SPID platform in providing PPI biomarkers for the emerging class of PPI-modulating drugs.”
Furthermore, through this project, PROTEINA aims to enhance the technological competitiveness of PPI PathFinder and the SPID platform and plans to supply the solution to overseas CLIA-certified labs based on the results of this exploratory clinical study.
About PROTEINA
Founded in 2015 in Seoul, PROTEINA is a leader in proteomics, enhancing drug research with its innovative Single-molecule Protein Interaction Detection (SPID) technology. This platform provides exceptional sensitivity for detecting protein-protein interactions, essential for pharmaceutical R&D. Serving top pharmaceutical companies and academic institutions worldwide, PROTEINA’s technology advances understanding of human biology, supporting modern healthcare solutions. With collaborations across Europe and North America, PROTEINA delivers insights that propel drug development and proteomic research.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240428101218/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Nemluvio® (Nemolizumab) for Patients with Moderate-to-Severe Atopic Dermatitis13.12.2024 23:09:00 CET | Press release
Ad hoc announcement pursuant to Art. 53 LR Approximately 7% of people in the United States (U.S.) have atopic dermatitis – a common, chronic, and flaring inflammatory skin disease, characterized by persistent itch and recurrent skin lesions1-4 While currently available treatments may improve some signs and symptoms of the disease, many patients do not respond optimally to approved therapies and do not experience itch relief and clear skin to the same degree2,5-7 Nemluvio® (nemolizumab) is the first approved monoclonal antibody that specifically targets IL-31 receptor alpha, inhibiting the signaling of IL-31. IL-31 is a neuroimmune cytokine that drives itch and is involved in inflammation and epidermal dysregulation in atopic dermatitis2,9-11 This approval follows Nemluvio’s recent approval for the treatment of adults with prurigo nodularis from the U.S. Food and Drug Administration earlier in August 202412 Galderma (SWX:GALD) today announced that the United States (U.S.) Food and Drug
Andersen Global forstærker sin dækning af Asien-Stillehavsregionen med ejendomsrådgivere i Australien13.12.2024 19:39:00 CET | Pressemeddelelse
Andersen Global styrker sin platform i Asien og Stillehavsregionen gennem en samarbejdsaftale med Charter Keck Cramer, der er et af Australiens førende, uafhængige ejendomsrådgivningsfirmaer. Det, der i 1970 begyndte som en lille virksomhed, Charter Keck Cramer, har siden udviklet sig til et tværfagligt firma med mere end 170 eksperter, der er fordelt på fem kontorer i Australien og Singapore. Firmaet tilbyder et omfattende udvalg af ejendomsrelaterede ydelser, herunder værdiansættelser inden for bolig- og erhvervsejendomme, ejendoms- og udviklingsrådgivning, ejendomsdata og analyser samt strategisk planlægning og byøkonomi samt kvantitetsopmåling. Charter Keck Cramer betjener en mangfoldig australsk og international kundebase, herunder offentlige og private virksomheder, ejere og udviklere, større banker og finansielle institutioner, institutionelle ejere og truster, statslige organer og familiekontorer. "Vores vækst over de seneste 54 år er drevet af vores uafhængige, skræddersyede t
Experian’s 2024 Global Identity & Fraud Report Spotlights Huge Growth in Highly Personalized GenAI-Driven Fraud Attacks13.12.2024 15:00:00 CET | Press release
Businesses Must Employ a Multi-Layered Approach to Fight GenAI Fraud Today, Experian announced its 2024 Global Identity & Fraud Report that provides a comprehensive view of the consumer and business response to the latest fraud patterns and fraud‑mitigation strategies in the worldwide financial services sector. The report offers combined insights from more than 1,000 businesses and fraud leaders globally, as well as 4,000 consumers, focusing on fraud management and the digital experience. Among its key insights, the report casts a bright spotlight on three factors driving the fast-evolving fraud landscape: the huge growth in Generative Artificial Intelligence (GenAI) technologies, changing government regulations, and the push among businesses to provide consumers with secure and convenient digital experiences. In response to these factors, the report’s findings revealed that businesses intend to increase fraud budgets driven by investments in AI and machine learning technologies. “Unli
Capcom Announces Onimusha Way of the Sword, Marking the First New Title in the Series in Over 20 Years! Work on an Okami Sequel Project Begins!13.12.2024 14:00:00 CET | Press release
Capcom Co., Ltd. (TOKYO:9697) today announced that Onimusha Way of the Sword, the first new title in the Onimusha series in over 20 years, is scheduled to be released, while work on an Okami sequel project has also started. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241213232085/en/ Onimusha Way of the Sword (Graphic: Business Wire) The Onimusha series consists of swordplay action games where players assume the role of warriors with the superhuman powers of the Oni and fight against monsters bent on world domination. Onimusha Way of the Sword, scheduled to be released globally in 2026, is a Japanese-inspired dark fantasy game set at the beginning of the Edo period in Kyoto, which has been eerily transformed by clouds of Malice. In the game, the samurai protagonist is equipped with the Oni Gauntlet and engages in epic sword battles with the grotesque and otherworldly creatures known as Genma. Capcom hopes that players loo
BrightPath Bio and Cellistic Announces Process Development and Manufacturing Collaboration for Phase 1 Clinical Trial of iPSC-derived BCMA CAR-iNKT cell13.12.2024 13:51:00 CET | Press release
BrightPath Bio (Tokyo Stock Exchange Growth 4594, “BrightPath”), a pioneer in iPS cell-derived Natural Killer T (“NKT”) cell therapy, and Cellistic, a leader in advanced iPS cell therapy manufacturing, today announced a process development and manufacturing agreement to advance BrightPath’s novel allogeneic CAR-T cell therapy platform, utilizing iPSC-derived NKT cells for clinical trials. The strategic collaboration includes the use of Cellistic's innovative 3D bioreactor-based manufacturing platform, Echo, to enable GMP-compliant, clinical-scale manufacturing of iPSC-derived BCMA-targeting CAR-NKT cells for Phase 1 multiple myeloma trial; establishing BrightPath as a first mover in this emerging field. “The use of NKT cells as effectors in allogeneic CAR-T therapy represents a promising strategy, offering not only direct cytotoxicity but also indirect anti-tumor activity through the priming of host CD8+ T cells—a mechanism expected to evade host immune rejection and to enhance the dur
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom